nr |
titel |
auteur |
tijdschrift |
jaar |
jaarg. |
afl. |
pagina('s) |
type |
1 |
ABC efflux transporters and drug toxicity
|
Schuetz, John |
|
2019 |
34 |
1S |
p. S6 |
artikel |
2 |
ABC xenobiotic transporters play important roles in systemic exposure and dermal distribution of tyrosine kinase inhibitor regorafenib and its active metabolites
|
Katov, Yukio |
|
2019 |
34 |
1S |
p. S73 |
artikel |
3 |
Academic and industry perspectives on pharmacogenomics: drug optimization
|
Shuldiner, Alan |
|
2019 |
34 |
1S |
p. S6 |
artikel |
4 |
Acceleration of murine hepatocyte proliferation by imazalil through the activation of nuclear receptor PXR
|
Yoshinari, Kouichi |
|
2019 |
34 |
1S |
p. S51 |
artikel |
5 |
Activity-based proteomics – protein and ligand discovery on a global scale
|
Cravatt, Benjamin |
|
2019 |
34 |
1S |
p. S14 |
artikel |
6 |
A direct comparison of assay detection methods for the assessment of transporter-mediated drug interactions
|
Sayer, Rachel |
|
2019 |
34 |
1S |
p. S77 |
artikel |
7 |
Adverse effects of psychiatric drugs on bone: Does drug distribution to marrow play a role?
|
Houseknecht, Karen |
|
2019 |
34 |
1S |
p. S31 |
artikel |
8 |
A Facile chemical derivatization method to discern the identity of glucronide conjugates of carboxylic acid drugs under mild conditions
|
Wang, Kai |
|
2019 |
34 |
1S |
p. S62 |
artikel |
9 |
A human liver microphysiology system for drug discovery and development
|
Taylor, D. Lansing |
|
2019 |
34 |
1S |
p. S9 |
artikel |
10 |
Aldehyde oxidase activity in human vascular tissue and its potential contribution to extra-hepatic metabolism
|
Kozminski, Kirk |
|
2019 |
34 |
1S |
p. S62-S63 |
artikel |
11 |
Ameliorating effect of baicalin in cadmium induced kidney fibrosis
|
Siddarth, Manushi |
|
2019 |
34 |
1S |
p. S18-S19 |
artikel |
12 |
Amiloride as a probe substrate for investigation of organic cation transport system
|
Kaneko, Chisa |
|
2019 |
34 |
1S |
p. S73 |
artikel |
13 |
A mouse model for investigating human brain CYP2D6
|
Tolledo, Edgor Cole |
|
2019 |
34 |
1S |
p. S15 |
artikel |
14 |
An efficient high throughput 96-well plated human hepatocytes assay for drug uptake and uptake transporter inhibition
|
Li, Albert P. |
|
2019 |
34 |
1S |
p. S48 |
artikel |
15 |
A new CYP-silenced CELL-Based assay for direct measurement of the contribution of major cytochrome P450 enzymes to drug clearance/metabolism
|
Sharma, Ashwani |
|
2019 |
34 |
1S |
p. S28 |
artikel |
16 |
Animal models for drug transporters
|
Bow, Daniel |
|
2019 |
34 |
1S |
p. S1 |
artikel |
17 |
An integrated in vitro screen using sandwich-cultured human hepatocytes for prediction of cholestatic hepatotoxicity
|
Jackson, Jonathan |
|
2019 |
34 |
1S |
p. S35 |
artikel |
18 |
A non-linear mixed-effects model to describe the population pharmacokinetics of mycophenolic acid and the effects of co-variates in adult, de-novo kidney transplant patients on steroid-free anti-rejection regimens
|
Rong, Yan |
|
2019 |
34 |
1S |
p. S65 |
artikel |
19 |
A novel ‘bottom-up’ physiologically based pharmacokinetic (PBPK) model of itraconazole and its metabolites: the importance of enzyme kinetics and protein binding
|
Garcia, Luna Prieto |
|
2019 |
34 |
1S |
p. S70-S71 |
artikel |
20 |
A Novel strategy for CYP3A4 Induction screening in drug discovery: use of heparg cells and simplified relative induction score method
|
Aratsu, Yusuke |
|
2019 |
34 |
1S |
p. S42 |
artikel |
21 |
A Pharmacokinetic natural product-disease-drug interaction: a double-hit on hepatic transporters
|
Clarke, John |
|
2019 |
34 |
1S |
p. S67-S68 |
artikel |
22 |
A physiologically based pharmacokinetic model (PBPK) utilizing specific muscle tissue for intramuscular injection of therapeutic proteins
|
Chow, Timothy |
|
2019 |
34 |
1S |
p. S19 |
artikel |
23 |
Apparent noncompetitive inhibition of BSEP in primary human hepatocytes associated with severe drug-induced liver injury
|
He, Kan |
|
2019 |
34 |
1S |
p. S72 |
artikel |
24 |
Application of DMPK toolbox in predicting human pharmacokinetics for back-up RIP1 inhibitors: Learnings from GSK2982772 in clinic
|
Mahajan, Mukesh |
|
2019 |
34 |
1S |
p. S66-S67 |
artikel |
25 |
Application of non-standard approaches to investigations of human mass balance and metabolite characterisation
|
Shaw, Iain |
|
2019 |
34 |
1S |
p. S38 |
artikel |
26 |
Application of PBPK modeling to evaluate pharmacokinetic drug-drug interactions during the development of new antimalarial combination therapies
|
Abla, Nada |
|
2019 |
34 |
1S |
p. S68-S69 |
artikel |
27 |
Are CYP3A5 expresser subpopulations at an increased risk for acetaminophen toxicity?
|
Mizuno, Kunihiko |
|
2019 |
34 |
1S |
p. S26 |
artikel |
28 |
Assessment of interaction with nucleosidal transporters between enasidenib and azacytidine
|
Yerramilli, Usha |
|
2019 |
34 |
1S |
p. S42 |
artikel |
29 |
Association of glutathione S-transferase genes (GSTM1 AND GSTT1) with blood lead levels in occupationally lead-exposed workers
|
Himani, |
|
2019 |
34 |
1S |
p. S78-S79 |
artikel |
30 |
Association of high blood lead levels with FOK1, APA1 and BSM1 Vitamin D Receptor gene polymorphism in occupationally exposed battery workers
|
Himani, |
|
2019 |
34 |
1S |
p. S28-S29 |
artikel |
31 |
ATP-Binding cassette transporters and CYP450 Isoforms are possible sites of ribociclib drug interactions
|
Sorf, Ales |
|
2019 |
34 |
1S |
p. S41 |
artikel |
32 |
Author Index
|
|
|
2019 |
34 |
1S |
p. I-VI |
artikel |
33 |
AZ1 – A CYP3A4 inducer with a complex DDI prediction analysis
|
Grime, Ken |
|
2019 |
34 |
1S |
p. S11 |
artikel |
34 |
BBB-on-a-chip: A 3D In vitro model of the human blood-brain barrier
|
Lowman, John |
|
2019 |
34 |
1S |
p. S54 |
artikel |
35 |
Bioinformatics: Accumulating and implementing pharmacogenomics information
|
Whirl-Carrillo, Michelle |
|
2019 |
34 |
1S |
p. S6 |
artikel |
36 |
Biotransformation of ADCs. Pathways and enzymes
|
Zhang, Donglu |
|
2019 |
34 |
1S |
p. S13 |
artikel |
37 |
Biotransformation of Pyrrolizidine alkaloid N-Oxide to hepatotoxic Pyrrolizidine alkaloid
|
Lin, Ge |
|
2019 |
34 |
1S |
p. S58-S59 |
artikel |
38 |
Can transporter-expressing cells predict rosuvastatin uptake clearance in suspended or plated human hepatocytes?
|
Kumar, Vineet |
|
2019 |
34 |
1S |
p. S22-S23 |
artikel |
39 |
Case studies in quality levels for in vitro adme assays: Hepatocyte stability
|
Sierra, Teresa |
|
2019 |
34 |
1S |
p. S50-S51 |
artikel |
40 |
Cellular distribution of biologics: A comparison of microautoradiography techniques
|
Harris, Stephen |
|
2019 |
34 |
1S |
p. S32 |
artikel |
41 |
Characterising the immune response to carbamazepine: Understanding the development of idiosyncratic drug reactions
|
Jee, Alison |
|
2019 |
34 |
1S |
p. S51-S52 |
artikel |
42 |
Characterization and ADME properties of a novel auristatin payload-based ADC
|
Leal, Mauricio |
|
2019 |
34 |
1S |
p. S9 |
artikel |
43 |
Characterization of antihypertensive drugs as potent inhibitors of CYP2J2
|
Yamaori, Satoshi |
|
2019 |
34 |
1S |
p. S46 |
artikel |
44 |
Characterization of cisplatin toxicity in aproximate human proximal tubule cell monolayers
|
Brown, Colin |
|
2019 |
34 |
1S |
p. S52-S53 |
artikel |
45 |
Characterization of CYP2C Induction in Cryopreserved human hepatocytes and ITS Application in the prediction of the clinical consequences of the induction
|
Nagai, Mika |
|
2019 |
34 |
1S |
p. S43 |
artikel |
46 |
Characterization of GCDC transport by human hepatic uptake transporters for in vitro testing purposes
|
Toth, Beata |
|
2019 |
34 |
1S |
p. S77 |
artikel |
47 |
Characterization of human hepatocytes by quantitative dmet proteomics addresses lot-to-lot variability: relevance in In-vitro to In-vivo extrapolation of hepatic drug clearance
|
Prasad, Bhagwat |
|
2019 |
34 |
1S |
p. S23-S24 |
artikel |
48 |
Characterization of individual differences in CYP3A5 Activity using a CYP3A5-Selective marker reaction in vitro
|
Jackson, Klarissa |
|
2019 |
34 |
1S |
p. S25-S26 |
artikel |
49 |
Characterization of the CYP and UGT enzymes involved in reactive metabolite generation from bromfenac and bromfenac indolinone
|
Yadav, Aprajita |
|
2019 |
34 |
1S |
p. S62 |
artikel |
50 |
Chemical-induced toxicity is ameliorated by swimming exercise in caenorhabditis elegans
|
Hartman, Jessica |
|
2019 |
34 |
1S |
p. S30 |
artikel |
51 |
Circulating hormones and nuclear hormone receptor expression are associated with treatment-free survival in patients with chronic lymphocytic leukemia
|
Allain, Eric |
|
2019 |
34 |
1S |
p. S29 |
artikel |
52 |
Clinical validation and utility of coproporphyrins as endogenous probes to predict OATP1B-mediated drug-drug interactions
|
Shen, Hong |
|
2019 |
34 |
1S |
p. S12 |
artikel |
53 |
CO-Culture of primary hepatic stellate cells and hepatocytes in modeling of liver fibrosis in 2D and 3D Spheroids
|
Witek, Rafal |
|
2019 |
34 |
1S |
p. S56 |
artikel |
54 |
Comparative biotransformation and mass-balance of [14C] BMS-986205, an inhibitor of IDO1, after oral administration to rats, dogs and humans
|
Liu-kreyche, Peggy |
|
2019 |
34 |
1S |
p. S59 |
artikel |
55 |
Comparative changes in renal gene expressions in chronic kidney disease and vitamin D deficient mouse models
|
Noh, Keumhan |
|
2019 |
34 |
1S |
p. S18 |
artikel |
56 |
Comprehensive hepatocellular disposition profiling of parent compound and its major metabolites in sandwich-cultured PXB-cells by D-PREX
|
Kanda, Katsuhiro |
|
2019 |
34 |
1S |
p. S53-S54 |
artikel |
57 |
Considerations from the IQ Induction working group in response to drug-drug interaction guidances from regulatory agencies
|
Hariparsad, Niresh |
|
2019 |
34 |
1S |
p. S11 |
artikel |
58 |
Contribution of hepatic FMO-1 in the metabolism of compound 1. Implication of clearance mechanism and extrapolation of metabolism data from preclinical species to humans
|
Bowlin, Steve |
|
2019 |
34 |
1S |
p. S30 |
artikel |
59 |
Contribution of UGT1A1, CYP2A6, CYP2C9, and CYP3A4 in metabolism of belinostat
|
Luo, Gang |
|
2019 |
34 |
1S |
p. S59 |
artikel |
60 |
Cope elimination mediated by human FMO1 leads to formation of reactive Michael Acceptor intermediate
|
Lai, Weidong |
|
2019 |
34 |
1S |
p. S58 |
artikel |
61 |
Covalent binding – from 20th century liability to 21st century targeted therapies
|
Slatter, Greg |
|
2019 |
34 |
1S |
p. S14 |
artikel |
62 |
Covalent binding of trimethoprim: Implications for trimethoprim-induced adverse reactions
|
Cao, Yanshan |
|
2019 |
34 |
1S |
p. S20 |
artikel |
63 |
Cryopreserved human intestinal mucosa: a novel in vitro 3-D Organ culture for the evaluation of P450 Induction in human intestines
|
Li, Albert P. |
|
2019 |
34 |
1S |
p. S43 |
artikel |
64 |
Cryopreserved human intestinal mucosa as a 3-Dimensional organoid culture for the evaluation of inestinal drug metabolism, drug-drug interactions, enterotoxicity, and enteropharmacology
|
Li, Albert P. |
|
2019 |
34 |
1S |
p. S46 |
artikel |
65 |
Cytochrome P450 3A enzyme-dependent thalidomide toxicity and inducibility in cultured human placental cells
|
Murayama, Norie |
|
2019 |
34 |
1S |
p. S27 |
artikel |
66 |
Cytotoxicity in primary human hepatocytes exposed to various microcystin congeners
|
Richardson, Vicki |
|
2019 |
34 |
1S |
p. S50 |
artikel |
67 |
Deep convolution neural netwroks analysis of chemical images: Applications in drug discovery and development
|
Koneti, Geervani |
|
2019 |
34 |
1S |
p. S35-S36 |
artikel |
68 |
DESI-MS imaging to observe the drug and drug-induced events in tumor tissue
|
Kim, Sang Kyoon |
|
2019 |
34 |
1S |
p. S34-S35 |
artikel |
69 |
Determining levels of methylenedianiline and toluenediamine as biomarkers for isocyanate exposure in human urine by UPLC-MS/MS
|
Lépine, Maggy |
|
2019 |
34 |
1S |
p. S21-S22 |
artikel |
70 |
Developing peptides therapeutics by understanding their metabolism and trafficking
|
Cancilla, Mark |
|
2019 |
34 |
1S |
p. S13 |
artikel |
71 |
Developmental immunotoxicity
|
Collinge, Mark |
|
2019 |
34 |
1S |
p. S4 |
artikel |
72 |
Development and validation of an LC-MS/MS method for vesicle assay using corning® Transportocells™ HEK293-derived ABC transporter membrane vesicles BCRP and MRP2
|
Cooper, Kirsten |
|
2019 |
34 |
1S |
p. S72 |
artikel |
73 |
Development of a discovery CYP Inhibition screen for early identification of DDI Liabilities
|
Sierra, Teresa |
|
2019 |
34 |
1S |
p. S38 |
artikel |
74 |
Development of a novel orally active inverse agonist of estrogen-related receptor gamma (ERRγ), KH-NDTC as an enhancer for sodium iodide symporter: Its pharmacological effects in anaplastic thyroid cancer (ATC) in vitro and in vivo
|
Jeon, Yong Hyun |
|
2019 |
34 |
1S |
p. S34 |
artikel |
75 |
Development of a novel predictive in vitro non human primate proximal tubule model for drug transporter and nephrotoxicity studies
|
Brown, Colin |
|
2019 |
34 |
1S |
p. S53 |
artikel |
76 |
Development of a quantitative bioanalytical method for the assessment of benserazide in pre-clinical samples
|
Wang, Amy Q. |
|
2019 |
34 |
1S |
p. S38 |
artikel |
77 |
Development of endogenous biomarkers for CYP3A to be used in drug interaction studies
|
Andersson, Tommy |
|
2019 |
34 |
1S |
p. S11-S12 |
artikel |
78 |
Development of UGT1A7 and UGT1A8 Inhibition assays using recombinant enzymes as a test system
|
Singh, Ritu |
|
2019 |
34 |
1S |
p. S45 |
artikel |
79 |
Different measures of varenicline adherence, nicotine metabolite ratio and smoking abstinence
|
Peng, Annie R. |
|
2019 |
34 |
1S |
p. S16-S17 |
artikel |
80 |
Disentangling host and microbiome contributions to drug pharmacokinetics and toxicity
|
Goodman, Andrew |
|
2019 |
34 |
1S |
p. S11 |
artikel |
81 |
Distribution and excretion of a new oral formulation of docetaxel in mice
|
Kim, Byoung Soo |
|
2019 |
34 |
1S |
p. S31 |
artikel |
82 |
Distribution and pharmacokinetics of 3H-Gemcitabine after single and multiple intraperitoneal treatment alone and in combination with intravenous docetaxel in BXPC-3 tumor bearing mice
|
Spencer, Elizabeth |
|
2019 |
34 |
1S |
p. S32 |
artikel |
83 |
Does plasma membrane and total transporter abundance differ between suspended, plated, sandwich culture hepatocytes and human liver tissue?
|
Kumar, Vineet |
|
2019 |
34 |
1S |
p. S17 |
artikel |
84 |
Drug-microbe interactions in HIV transmission
|
Klatt, Nichole |
|
2019 |
34 |
1S |
p. S10-S11 |
artikel |
85 |
Drug target quantitation, translational PK/PD
|
Palandra, Joe |
|
2019 |
34 |
1S |
p. S13 |
artikel |
86 |
Dysregulation of transporters in maternal disease; potential impact on fetal drug exposure
|
Piquette-Miller, Micheline |
|
2019 |
34 |
1S |
p. S7 |
artikel |
87 |
Effective inhibition of CYP3A4-Dependent drug oxidation by anti-CYP3A4 Antibodies in metmax cryopreserved human hepatocytes
|
Li, Albert P. |
|
2019 |
34 |
1S |
p. S49 |
artikel |
88 |
Effect of age on brain exposure of P-GP substrates in neonatal rats
|
Rooney, Michael |
|
2019 |
34 |
1S |
p. S31 |
artikel |
89 |
Effect of renal transplantation on organochlorine pesticide (OCPS) Levels in chronic kidney disease patients (CKD-5D): A Longitudinal study
|
Himani, Amit Kumar |
|
2019 |
34 |
1S |
p. S64 |
artikel |
90 |
Effects of essential oils of culinary herbs and spices on the CYP3A4 Expression in primary human hepatocytes and cell lines
|
Bartonkova, Iveta |
|
2019 |
34 |
1S |
p. S39-S40 |
artikel |
91 |
Effects of mycophenolic acid and clinical variables on tacrolimus exposure in de novo, steroid-free adult renal transplant patients
|
Kiang, Tony KL. |
|
2019 |
34 |
1S |
p. S66 |
artikel |
92 |
Effects of PEG200 and PEG400 on human renal uptake/efflux transporters
|
Houle, Robert |
|
2019 |
34 |
1S |
p. S72 |
artikel |
93 |
Effects of thyroparathyroidectomy on clinical pathology and bone density in the rat
|
Poulin, Dominic |
|
2019 |
34 |
1S |
p. S37-S38 |
artikel |
94 |
Elimination of [14C] LY3023414 by aldehyde oxidase and CYP enzymes in humans following oral administration
|
Zhou, Lian |
|
2019 |
34 |
1S |
p. S63 |
artikel |
95 |
Endogenous biomarkers for drug metabolism and transporter activity
|
Giacomini, Kathy |
|
2019 |
34 |
1S |
p. S12 |
artikel |
96 |
Enhanced metabolite identification using orbitrap tribrid mass spectrometer
|
Comstock, Kate |
|
2019 |
34 |
1S |
p. S32-S33 |
artikel |
97 |
Environmental xenobiotics safety assessment through comparative metabolism study in fish, swine, goat, chicken, rat and human
|
Ma, Mingming |
|
2019 |
34 |
1S |
p. S30 |
artikel |
98 |
Equilibrative nucleoside transporter 1 (ENT1) facilitates transfer of the antiretroviral drug abacavir across the placenta
|
Cerveny, Lukas |
|
2019 |
34 |
1S |
p. S71-S72 |
artikel |
99 |
Established chemical knockout condition for P-GP mediated efflux at the blood-brain-barrier in cynomolgus monkey
|
Nakakariya, Masanori |
|
2019 |
34 |
1S |
p. S76 |
artikel |
100 |
Establishment of albumin-deficient NOG mice as a useful model for drug discovery research
|
Suemizu, Hiroshi |
|
2019 |
34 |
1S |
p. S20 |
artikel |
101 |
Estimating efflux transporter-mediated disposition using transporter gene knockout rats
|
Miyake, Taiji |
|
2019 |
34 |
1S |
p. S21 |
artikel |
102 |
Evaluation of a pre-constructed relative induction score (RIS) curve for prediction of CYP3A4 induction response in vivo
|
Zhang, George |
|
2019 |
34 |
1S |
p. S44-S45 |
artikel |
103 |
Evaluation of the time-course of CYP Induction and impact on drug interaction risk assessment from the IQ Induction working group
|
Hariparsad, Niresh |
|
2019 |
34 |
1S |
p. S40 |
artikel |
104 |
Expanded primary human liver sinusoidal endothelial cells as a predictive tool in hepatotoxicity evaluation
|
Noerenberg, Astrid |
|
2019 |
34 |
1S |
p. S51 |
artikel |
105 |
Experimental approaches to understand intracellular based drug bioavailability
|
Artursson, Per |
|
2019 |
34 |
1S |
p. S3 |
artikel |
106 |
Expression and induction ability of cytochrome P450 in human hepatocytes isolated from chimeric mice with humanized livers
|
Uehara, Shotaro |
|
2019 |
34 |
1S |
p. S44 |
artikel |
107 |
Expression of concentrative nucleoside transporters (SLC28A) in the human placenta; effects of gestation age and prototype differentiation-affecting agents
|
Jiraskova, Lucie |
|
2019 |
34 |
1S |
p. S73 |
artikel |
108 |
Ex vivo whole liver perfusion model for prediction of drug-drug interactions and biliary excretion of rosuvastatin
|
van de Steeg, Evita |
|
2019 |
34 |
1S |
p. S48 |
artikel |
109 |
Factors that influence tranexamic acid overdose in cardiac surgical patients with chronic renal dysfunction
|
Yang, Qi |
|
2019 |
34 |
1S |
p. S68 |
artikel |
110 |
Future perspectives related to hepatic enzyme induction
|
LeCluyse, Edward |
|
2019 |
34 |
1S |
p. S11 |
artikel |
111 |
Generation of reproducible predictive models using parallelized modified teaching learning based search optimization method and its applications in drug discovery and development
|
Koneti, Geervani |
|
2019 |
34 |
1S |
p. S36 |
artikel |
112 |
Genetic predictors and underlying mechanism of treatment-related complications in childhood acute lymphoblastic leukemia
|
Krajinovic, Maja |
|
2019 |
34 |
1S |
p. S8 |
artikel |
113 |
Genome-guided medications for safer and more effective treatment of disease
|
Ross, Colin |
|
2019 |
34 |
1S |
p. S8 |
artikel |
114 |
Genotype-sensitive reversible and time-dependent CYP2D6 Inhibition in human liver microsomes
|
Storelli, Flavia |
|
2019 |
34 |
1S |
p. S41-S42 |
artikel |
115 |
Hepatic 3D spheroids: an in vitro tool for studying hepatic function and drug toxicity
|
Lahiri, Sujoy |
|
2019 |
34 |
1S |
p. S49 |
artikel |
116 |
Hepatobiliary transporter expression and functional uptake of substrates in 2D sandwich cultures using upcyte® hepatocytes
|
Noerenberg, Astrid |
|
2019 |
34 |
1S |
p. S76 |
artikel |
117 |
High-throughput kidney proximal tubules-on-a-chip for predictive renal toxicity screening
|
Saleh, Anthony |
|
2019 |
34 |
1S |
p. S55 |
artikel |
118 |
High-Throughput Liver-ON-A-Chip for predictive hepatotoxicity screening
|
Saleh, Anthony |
|
2019 |
34 |
1S |
p. S50 |
artikel |
119 |
High-throughput, perfused intestinal tubules for real-time assessment of drug-induced barrier disruption
|
Lowman, John |
|
2019 |
34 |
1S |
p. S54 |
artikel |
120 |
How to be selectively promiscuous
|
Taunton, Jack |
|
2019 |
34 |
1S |
p. S14 |
artikel |
121 |
Human amyloid-beta 1-40 disposition after intravenous and intracerebral injections in the rat
|
Peng, Hao Benson |
|
2019 |
34 |
1S |
p. S65 |
artikel |
122 |
Human ex vivo model to study intestinal processes and microbiome induced metabolism
|
Stevens, Lianne |
|
2019 |
34 |
1S |
p. S55-S56 |
artikel |
123 |
Identification of dopa-modified amino acids using high-resolution tandem mass spectrometry
|
Sansoucy, Maxime |
|
2019 |
34 |
1S |
p. S25 |
artikel |
124 |
Identification of metabolomic biomarkers for endometrial cancer and its recurrence after surgery in postmenopausal women
|
Audet-Delage, Yannick |
|
2019 |
34 |
1S |
p. S29-S30 |
artikel |
125 |
Immunological components of liver injury
|
Ju, Cynthia |
|
2019 |
34 |
1S |
p. S4 |
artikel |
126 |
Immuno oncology state-of-the-field and how it helps understand the immune system and mechanisms for drug efficacy and toxicity
|
Hollenbaugh, Diane |
|
2019 |
34 |
1S |
p. S5 |
artikel |
127 |
Impact of hepatic drug distribution on predictions of clearance
|
Sodhi, Jasleen K. |
|
2019 |
34 |
1S |
p. S23 |
artikel |
128 |
Influence of dichloroacetate treatment on the contributions of rodent brain, heart, liver and kidney in the activity of GSTZ1
|
Squirewell, Edwin |
|
2019 |
34 |
1S |
p. S46-S47 |
artikel |
129 |
Inhibition of lithocholic ACID 3-Oxidation by selective estrogen receptor modulators
|
Bansal, Sumit |
|
2019 |
34 |
1S |
p. S45 |
artikel |
130 |
Inhibition of solute carrier (SLC) transporter proteins using corning® transportocells™ for DDI assessment
|
Webber, Guy |
|
2019 |
34 |
1S |
p. S78 |
artikel |
131 |
Inhibition of UGT enzymes using recombinant UGT Enzymes for DDI Assessment
|
Webber, Guy |
|
2019 |
34 |
1S |
p. S45-S46 |
artikel |
132 |
In silico approaches to modeling transporter data
|
Varma, Manthena |
|
2019 |
34 |
1S |
p. S3 |
artikel |
133 |
IN-SILICO Tool to predict new CYP3A5 Silensomestm using T-5 Substrate and lapatinib as mechanism-based inhibitor
|
Martin, Solenne |
|
2019 |
34 |
1S |
p. S26 |
artikel |
134 |
Integrating pharmacokinetic-pharmacodynamic modeling in preclinical assessment of mutant selective EGFR covalent tyrosine kinase inhibitor EGF816
|
Li, Chun |
|
2019 |
34 |
1S |
p. S68 |
artikel |
135 |
Interactions of herbal slimming agents with CYP Substrates: an in vitro study using human liver microsomes
|
Nanjappan, Satheeshkumar |
|
2019 |
34 |
1S |
p. S55 |
artikel |
136 |
Interindividual variability in hepatic expression of human sulfotransferase 2A1: Absolute quantification by LC-MS/MS proteomics and effect of ethnicity, genotype, age and gender
|
Ladumor, Mayurbhai Kathadbhai |
|
2019 |
34 |
1S |
p. S16 |
artikel |
137 |
Intestinal absorption and rodent brain exposure estimated by low efflux cells
|
Pietrasiewicz, Alicia |
|
2019 |
34 |
1S |
p. S55 |
artikel |
138 |
Intracellular drug concentrations: Theory, practice, and promise
|
Smith, Dennis |
|
2019 |
34 |
1S |
p. S5 |
artikel |
139 |
Intra-tissue catabolite characterization is a missing link in discovery of ADCs
|
Zhang, Donglu |
|
2019 |
34 |
1S |
p. S9 |
artikel |
140 |
Introduction to the fundamentals of induction
|
Sinz, Michael |
|
2019 |
34 |
1S |
p. S2 |
artikel |
141 |
Investigating acetaminophen covalent protein binding to glutathione S-transferases by LC-MS/MS
|
Geib, Timon |
|
2019 |
34 |
1S |
p. S53 |
artikel |
142 |
Investigation of human organic anion transporting polypeptide 2B1 using fluorescent anions
|
Kawasaki, Tatsuya |
|
2019 |
34 |
1S |
p. S73-S74 |
artikel |
143 |
In vitro and in vivo catabolism of TAK-164, a gcc-targeted antibody-drug conjugate
|
Bolleddula, Jayaprakasam |
|
2019 |
34 |
1S |
p. S20-S21 |
artikel |
144 |
In vitro and in vivo mechanisms of ADC disposition and activity
|
Phipps, Colin |
|
2019 |
34 |
1S |
p. S9 |
artikel |
145 |
In vitro assessment of the relative toxicity of a series of pyrrolizidine alkaloids: Taking account of metabolic activation and toxicokinetics
|
Obringer, Cindy |
|
2019 |
34 |
1S |
p. S54 |
artikel |
146 |
In vitro characterization of ertugliflozin glucuronidation
|
Lapham, Kimberly |
|
2019 |
34 |
1S |
p. S24 |
artikel |
147 |
In vitro data fitting and interpretation
|
Kenny, Jane |
|
2019 |
34 |
1S |
p. S2 |
artikel |
148 |
In vitro-in vivo correlation of clearance for H3B-5942, a novel selective erα covalent antagonist (SERCA)
|
Colombo, Federico |
|
2019 |
34 |
1S |
p. S22 |
artikel |
149 |
In vitro metabolic and transporter profiling for maribavir (SHP620)
|
Welty, Devin |
|
2019 |
34 |
1S |
p. S61 |
artikel |
150 |
In vitro primary human hepatocyte 3D spheroid model for hepatotoxicity studies
|
Li, Feng |
|
2019 |
34 |
1S |
p. S36 |
artikel |
151 |
In vitro to in vivo extrapolation of intrinsic clearance for low turnover compounds using plated pooled donor human hepatocyte co-culture systems
|
Kazmi, Faraz |
|
2019 |
34 |
1S |
p. S52 |
artikel |
152 |
Keyword Index
|
|
|
2019 |
34 |
1S |
p. VII-VIII |
artikel |
153 |
Kidney transporters and nephrotoxicity
|
Masereeuw, Rosalinde |
|
2019 |
34 |
1S |
p. S5 |
artikel |
154 |
Lack of pharmacokinetic interaction between single oral doses of letermovir (MK-8228) and fluconazole in healthy subjects
|
Adedoyin, Adedayo |
|
2019 |
34 |
1S |
p. S39 |
artikel |
155 |
Lamisil (terbinafine): determining bioactivation pathways using computational modeling and experimental approaches
|
Barnette, Dustyn |
|
2019 |
34 |
1S |
p. S57 |
artikel |
156 |
LC-MS/MS Rapid identification of a novel tracer for a subtype specific phosphodiesterase (PDE) with no known ligand
|
Chen, Jie |
|
2019 |
34 |
1S |
p. S67 |
artikel |
157 |
Lignan enterolactone modulates cellular lipid and cholesterol homeostasis linking diverse molecular mechanisms
|
De Silva, Franklyn |
|
2019 |
34 |
1S |
p. S33 |
artikel |
158 |
Linked organs-on-chips for probing xenobiotic bioactivation, transport and toxicity
|
Kelly, Edward J. |
|
2019 |
34 |
1S |
p. S9-S10 |
artikel |
159 |
LST-3TM12 is a member of the OATP1B-family and a functional transporter influenced by genetic variants
|
Meyer zu Schwabedissen, Henriette |
|
2019 |
34 |
1S |
p. S75 |
artikel |
160 |
LST-3TM12 is part of the FXR modulated gene network in hepatocytes
|
Malagnino, Vanessa |
|
2019 |
34 |
1S |
p. S74-S75 |
artikel |
161 |
Mechanistic modeling of in vitro assays to improve in vitro/in vivo extrapolation
|
Fraczkiewicz, Grazyna |
|
2019 |
34 |
1S |
p. S3 |
artikel |
162 |
Metabolism of 3,7-dihydroxyflavone mediated by cytochrome P450
|
Bojic, Mirza |
|
2019 |
34 |
1S |
p. S25 |
artikel |
163 |
Metabolism of pevonedistat in patients with advanced solid tumors after intravenous infusion of [14C] pevonedistat
|
Chen, Hao |
|
2019 |
34 |
1S |
p. S57 |
artikel |
164 |
Metabolite profiling using dried blood spot
|
Katyayan, Kishore |
|
2019 |
34 |
1S |
p. S58 |
artikel |
165 |
Method development for the solubilization of biological matrices
|
Webber, Guy |
|
2019 |
34 |
1S |
p. S56 |
artikel |
166 |
Methylindoles and methoxyindoles are agonists and antagonists of human aryl hydrocarbon receptor AhR
|
Dvorak, Zdenek |
|
2019 |
34 |
1S |
p. S41 |
artikel |
167 |
Metmax human hepatocyte/HEK293 Cytotoxicity assay for the evaluation of metabolism dependent drug toxicity and identification of drug candidates forming cytotoxic reactive metabolites
|
Li, Albert P. |
|
2019 |
34 |
1S |
p. S49-S50 |
artikel |
168 |
Microphysiological systems in pharma: Evolving a paradigm
|
Proctor, William |
|
2019 |
34 |
1S |
p. S10 |
artikel |
169 |
Microsomal cytochrome P450 enzyme activities in nonalcoholic steatohepatitis livers
|
Czerwinski, Maciej |
|
2019 |
34 |
1S |
p. S25 |
artikel |
170 |
MRP4 (ABCC4) is a determinant of observed capecitabine and its metabolite concentrations during cancer therapy
|
Almousa, Ahmed A. |
|
2019 |
34 |
1S |
p. S64 |
artikel |
171 |
Mutations of flavin-containing monooxygenase 3 (FMO3) gene in Japanese cohorts
|
Shimizu, Makiko |
|
2019 |
34 |
1S |
p. S63 |
artikel |
172 |
N-acetylation capacity of N-acetyltransferase 2 in human peripheral blood mononuclear cells regulated by NAT2 genotype and sirtuin 1
|
Salazar-Gonzalez, Raul A. |
|
2019 |
34 |
1S |
p. S17 |
artikel |
173 |
Nonclinical immunotoxicity testing assessment
|
Wheeler, Jennifer |
|
2019 |
34 |
1S |
p. S4-S5 |
artikel |
174 |
Novel insights into predicting hepatic DDI liabilities when transporters and enzymes are involved
|
Patilea-Vrana, Gabriela |
|
2019 |
34 |
1S |
p. S15 |
artikel |
175 |
Novel in vitro models to study transporters
|
Lai, Yurong |
|
2019 |
34 |
1S |
p. S1 |
artikel |
176 |
Novel synthetic and computational approaches to the discovery of drugs targeting nonalcoholic fatty liver disease
|
Westlin, William |
|
2019 |
34 |
1S |
p. S6-S7 |
artikel |
177 |
On-target related immunotoxicity
|
Lee, Dong |
|
2019 |
34 |
1S |
p. S4 |
artikel |
178 |
Opportunities and challenges in the discovery of novel agents for the treatment of malaria
|
Burrows, Jeremy |
|
2019 |
34 |
1S |
p. S12-S13 |
artikel |
179 |
Optimization of stepped collision energies of hcd in orbitrap mass spectrometry for metabolite structure elucidation
|
Zhao, Jianwei |
|
2019 |
34 |
1S |
p. S38-S39 |
artikel |
180 |
Oxidative metabolism of synthetic cannabinoid STS-135 by recombinant P450S and human liver microsomes
|
Yarbrough, Azure |
|
2019 |
34 |
1S |
p. S28 |
artikel |
181 |
PBPK modeling of induction
|
Zhao, Ping |
|
2019 |
34 |
1S |
p. S11 |
artikel |
182 |
Pegylated crushed gold shell-radiolabeled core nanoballs for in vivo tumor imaging with dual positron emission tomography and cerenkov luminescent imaging
|
Jeon, Yong Hyun |
|
2019 |
34 |
1S |
p. S47 |
artikel |
183 |
Pet imaging to understand hepatobiliary transporters
|
Sugiyama, Yuichi |
|
2019 |
34 |
1S |
p. S1 |
artikel |
184 |
Pharmacogenomics in drug response and safety assessment
|
Daly, Ann |
|
2019 |
34 |
1S |
p. S6 |
artikel |
185 |
Pharmacokinetic changes in pregnancy: Clinical implications
|
Ito, Shinya |
|
2019 |
34 |
1S |
p. S7 |
artikel |
186 |
Phosphorylated nuclear receptors as drug-targets
|
Negishi, Masahiko |
|
2019 |
34 |
1S |
p. S2 |
artikel |
187 |
Physiologically based pharmacokinetic model predictions of ivosidenib (AG-120) as a victim and perpetrator of drug–drug interactions
|
Prakash, Chandra |
|
2019 |
34 |
1S |
p. S70 |
artikel |
188 |
Polymorphisms in canine glutathione S-Transferase (GST) genes: Prevalence and functional relevance
|
Sacco, James |
|
2019 |
34 |
1S |
p. S24 |
artikel |
189 |
Population pharmacokinetics of immediate-release tacrolimus in steroid-free adult renal transplant recipients
|
Rong, Yan |
|
2019 |
34 |
1S |
p. S66 |
artikel |
190 |
Potential exposure to DI-2-Ethylhexyl terephthalate and DINCH, two phthalate replacements, in American adults
|
Silva, Manori |
|
2019 |
34 |
1S |
p. S60-S61 |
artikel |
191 |
Preclinial biopharmaceutics and pharmacokinetic characterization of an HIV-1 Replication inhibitor DB213
|
Zuo, Zhong |
|
2019 |
34 |
1S |
p. S39 |
artikel |
192 |
Preclinical development of the PI3K Alpha selective and PIK3CA Mutant selective inhibitor GDC-0077 and prediction of its human pharmacokinetics
|
Pang, Jodie |
|
2019 |
34 |
1S |
p. S37 |
artikel |
193 |
Predicting and preventing the inactivation of drugs by human gut bacteria
|
Turnbaugh, Peter |
|
2019 |
34 |
1S |
p. S10 |
artikel |
194 |
Predicting and verifying maternal-fetal exposure to drugs during pregnancy
|
Unadkat, Jashvant |
|
2019 |
34 |
1S |
p. S7 |
artikel |
195 |
Prediction of adverse drug reactions of biased data using bootstrap aggregating and machine learning techniques
|
Ghosh, Dipayan |
|
2019 |
34 |
1S |
p. S33-S34 |
artikel |
196 |
Prediction of human hepatic clearance for cytochrome P450 substrates via a new culture method using the collagen vitrigel membrane chamber and PXB-cells
|
Watari, Ryuji |
|
2019 |
34 |
1S |
p. S23 |
artikel |
197 |
Prediction of human-specific metabolites of mianserin, cyproheptadine, and carbazeran using chimeric mice with humanized liver (PXB-MICE)
|
Kato, Suguru |
|
2019 |
34 |
1S |
p. S58 |
artikel |
198 |
Prediction of respiratory toxicity using chemical information and machine learning techniques
|
Ghosh, Dipayan |
|
2019 |
34 |
1S |
p. S34 |
artikel |
199 |
Predictive performance of Simcyp default models of 8 cytochrome P450 modulators in different clinical senarios
|
Samer, Caroline |
|
2019 |
34 |
1S |
p. S69 |
artikel |
200 |
Probe drugs for clinical transporter DDI Evaluation
|
Zamek-Gliszczynski, Maciej J. |
|
2019 |
34 |
1S |
p. S1 |
artikel |
201 |
Profiling of flavored non-alcoholic beverages toward trancriptional activity of PPAR gamma using a novel reporter cell line PAZ-PPARG
|
Illes, Peter |
|
2019 |
34 |
1S |
p. S63-S64 |
artikel |
202 |
Qualification and application of an in vitro liver model early in pharmaceutical development to help derisk drug-induced liver injury (DILI)
|
Mitra, Kaushik |
|
2019 |
34 |
1S |
p. S42 |
artikel |
203 |
Quality-by-design (QBD) approach to address rigor and reproducibility in dmet quantitative proteomics
|
Prasad, Bhagwat |
|
2019 |
34 |
1S |
p. S70 |
artikel |
204 |
Quantitation of plasma membrane drug transporters enables bottom-up PBPK modeling of transporter substrates
|
Kikuchi, Ryota |
|
2019 |
34 |
1S |
p. S74 |
artikel |
205 |
Quantitative determination of the effect of DDT and DDE treatments on CYP1 enzyme expression in MCF-7 Cells
|
Raccor, Brianne |
|
2019 |
34 |
1S |
p. S27-S28 |
artikel |
206 |
Quantitative investigation of OATP1B-mediated drug-drug interactions using endogenous substrates
|
Kusuhara, Hiroyuki |
|
2019 |
34 |
1S |
p. S12 |
artikel |
207 |
Quantitative mass balance, tissue distribution, pharmacokinetics and biotransformation pathway of praliciguat, a clinical-stage sgc stimulator, after oral administration in rats
|
Banijamali, Ali |
|
2019 |
34 |
1S |
p. S56-S57 |
artikel |
208 |
Quantitative prediction of CYP3A4 Induction using simple relative factor approach
|
Kuramoto, Shino |
|
2019 |
34 |
1S |
p. S42-S43 |
artikel |
209 |
Quantitative prediction of drug interaction potential between cobicistat and ruzasvir using a physiological based pharmacokinetic modeling approach
|
Wang, Ying-Hong |
|
2019 |
34 |
1S |
p. S71 |
artikel |
210 |
Quantitative prediction of metabolite exposures in humans using chimeric mice with humanized-liver
|
Watari, Ryosuke |
|
2019 |
34 |
1S |
p. S61-S62 |
artikel |
211 |
Rapid ADME screening for streamlined FDA submission; a case study assessing oral absorption validation and transporter substrate assessment of new molecular entities in wt caco-2 cells (C2BBEI)
|
Thomas, Kevin |
|
2019 |
34 |
1S |
p. S21 |
artikel |
212 |
Rapid CYP450 quantification by immunoaffinity-mass spectrometry
|
Pötz, Oliver |
|
2019 |
34 |
1S |
p. S27 |
artikel |
213 |
Reactive metabolite formation by irreversible and quasi-irreversible cytochrome P450 Inhibitors
|
Thomas, Jennifer |
|
2019 |
34 |
1S |
p. S40-S41 |
artikel |
214 |
Recommendations for in vitro CYP3A4 mRNA data analysis for drug-drug interaction risk assessment from the IQ Induction working group
|
Tweedie, Donald |
|
2019 |
34 |
1S |
p. S44 |
artikel |
215 |
Reduced parent-metabolite(s) physiologically-based pharmacokinetic model: Application to mycophenolic acid
|
Matsunaga, Norikazu |
|
2019 |
34 |
1S |
p. S69 |
artikel |
216 |
Regulatory requirements to assess induction
|
Berglund, Eva Gil |
|
2019 |
34 |
1S |
p. S11 |
artikel |
217 |
Relative activity factor (RAF)-based scaling of uptake clearance of OATP1B substrates from transfected cell systems to human hepatocytes and to in vivo
|
Izumi, Saki |
|
2019 |
34 |
1S |
p. S19 |
artikel |
218 |
Resistance mediated by lysosomal sequestration of anticancer agents in vitro
|
Mlejnek, Petr |
|
2019 |
34 |
1S |
p. S21 |
artikel |
219 |
Revisiting evaluation of CYP2C9 and CYP2C19 Induction in vitro: potential for robust induction responses with ≥ 4-Day hepatocyte exposure times
|
Stresser, David |
|
2019 |
34 |
1S |
p. S43-S44 |
artikel |
220 |
RPL28 Promoter polymorphism RS4806668 is associated with reduced survival in folfiri-treated metastatic colorectal cancer patients
|
Labriet, Adrien |
|
2019 |
34 |
1S |
p. S64-S65 |
artikel |
221 |
Screening for phase I and phase II drug metabolism using supplemented liver and intestinal S9 fractions: A cocktail approach
|
Thomas, Kevin |
|
2019 |
34 |
1S |
p. S24-S25 |
artikel |
222 |
Semi-physiologically based pharmacokinetic model allows prediction of CNS disposition of ONO-2333MS in humans
|
Matsunaga, Norikazu |
|
2019 |
34 |
1S |
p. S69-S70 |
artikel |
223 |
Sequential metabolism kinetics of Δ9-Tetrahydrocannabinol (THC) and ITS Psychoactive 11-OH-THC Metabolite
|
Patilea-Vrana, Gabriela |
|
2019 |
34 |
1S |
p. S60 |
artikel |
224 |
Sex differences in brain oxycodone metabolism and analgesia
|
Arguelles, Nicole |
|
2019 |
34 |
1S |
p. S29 |
artikel |
225 |
Simultaneous assessment of transporter drug–drug interactions using a probe drug cocktail in cynomolgus monkey
|
Varma, Manthena |
|
2019 |
34 |
1S |
p. S77 |
artikel |
226 |
Simultaneous measurements of N1-methylnicotinamide, creatinine, isobutyryl-L-carnitine by liquid chromatograph with high resolution mass spectrometry for assessing the activities of multiple renal cationic transporters in first-in-human clinical trial
|
Luo, Lina |
|
2019 |
34 |
1S |
p. S74 |
artikel |
227 |
Simultaneous modeling of metabolism, competitive and mechanism based inhibition
|
Burt, Howard |
|
2019 |
34 |
1S |
p. S3-S4 |
artikel |
228 |
Site-specific deuterium substitution: A viable approach in drug discovery and development
|
Bradbury, Margaret |
|
2019 |
34 |
1S |
p. S8-S9 |
artikel |
229 |
Steroidal anti-androgens inhibit lithocholic acid sulfonation and increase lithocholic acid-induced toxicity in a human hepatocellular carcinoma cell model
|
Wong, Siew Ying |
|
2019 |
34 |
1S |
p. S18 |
artikel |
230 |
Studying the metabolism of sunscreen compounds in vitro by LC-MS/MS
|
Guesmi, Amal |
|
2019 |
34 |
1S |
p. S57-S58 |
artikel |
231 |
Substrate-dependent interactions between natural flavonoids and drug transporter OATP2B1
|
Nabekura, Tomohiro |
|
2019 |
34 |
1S |
p. S75-S76 |
artikel |
232 |
Systems pharmacokinetic modeling of ADCs
|
Shah, Dhaval |
|
2019 |
34 |
1S |
p. S9 |
artikel |
233 |
Tanshinone IIA reverses rifampicin-induced liver injury via activating NRF2-mediated regulation of human NTCP transporter expression
|
Yang, Yujie |
|
2019 |
34 |
1S |
p. S78 |
artikel |
234 |
Targeted covalent inhibitors for drug design
|
Baillie, Thomas |
|
2019 |
34 |
1S |
p. S13-S14 |
artikel |
235 |
Technical considerations for evaluating human liver enzyme induction potential
|
Ferguson, Stephen |
|
2019 |
34 |
1S |
p. S2 |
artikel |
236 |
The combined application of long term hepatic co-culture and RNA interference for reaction phenotyping: lessons learned
|
Borel, Anthony |
|
2019 |
34 |
1S |
p. S49 |
artikel |
237 |
The development of a CRISPR/Cas-mediated PD-1 knockout rat model to study idiosyncratic drug reactions including nevirapine-induced liver injury
|
Cho, Tiffany |
|
2019 |
34 |
1S |
p. S15-S16 |
artikel |
238 |
The hurdle of human PK Predictions for hepatic oatp substrates: lessons learned from rat allometry
|
Mei, Hong |
|
2019 |
34 |
1S |
p. S67 |
artikel |
239 |
The impact of plasma protein binding on the tissue distribution of warfarin - investigation in nagase analbuminemic rats (NAR)
|
Pang, Jodie |
|
2019 |
34 |
1S |
p. S37 |
artikel |
240 |
The phenotyping of solute carrier transporters in human primary hepatocytes
|
Bi, Yi-an |
|
2019 |
34 |
1S |
p. S71 |
artikel |
241 |
Therapeutic targeting of the pyruvate dehydrogenase complex/pyruvate dehydrogenase kinase (PDC/PDK) axis for congenital and acquired metabolic diseases
|
Stacpoole, Peter |
|
2019 |
34 |
1S |
p. S61 |
artikel |
242 |
The role of nucleoside transporters in entecavir transport across placenta
|
Karbanova, Sara |
|
2019 |
34 |
1S |
p. S40 |
artikel |
243 |
The role of reductases in drug discovery and development
|
Di, Li |
|
2019 |
34 |
1S |
p. S62 |
artikel |
244 |
The utility of liver spheroids in addressing current issues in drug metabolism and liver toxicity evaluations
|
Gan, Jinping |
|
2019 |
34 |
1S |
p. S10 |
artikel |
245 |
Tissue-specific mechanisms of irinotecan metabolism
|
Vrana, Marc |
|
2019 |
34 |
1S |
p. S47 |
artikel |
246 |
Title page
|
|
|
2019 |
34 |
1S |
p. i |
artikel |
247 |
TOC
|
|
|
2019 |
34 |
1S |
p. ii-iv |
artikel |
248 |
Toxicogenomics and systems toxicology approaches to understanding adverse outcomes
|
Willy, Jeffrey |
|
2019 |
34 |
1S |
p. S8 |
artikel |
249 |
Transcriptomic biomarkers to assess the liver and metabolic responses associated with bioactivation mechanisms of drug induced liver injury
|
Monroe, James |
|
2019 |
34 |
1S |
p. S36 |
artikel |
250 |
Transporters and arsenic toxicity
|
Leslie, Elaine |
|
2019 |
34 |
1S |
p. S6 |
artikel |
251 |
Transporters and drug-induced liver injury
|
Brouwer, Kim |
|
2019 |
34 |
1S |
p. S5 |
artikel |
252 |
Understanding DMPK of biotherapeutics using intact protein bioanalysis
|
Jian, Wenying |
|
2019 |
34 |
1S |
p. S13 |
artikel |
253 |
Understanding the translational capability of in vitro active hepatic OATP uptake data using PBPK modeling
|
Bowman, Christine |
|
2019 |
34 |
1S |
p. S47-S48 |
artikel |
254 |
Unraveling the metabolic fate of potential therapeutic dimer compounds for Parkinson’s disease
|
Nwabufo, Chukwunonso |
|
2019 |
34 |
1S |
p. S59-S60 |
artikel |
255 |
UP-regulation of ATP-binding cassette transporters in the placenta during PRE-eclampsia and the potential role of NRF2
|
Yu, Lu |
|
2019 |
34 |
1S |
p. S78 |
artikel |
256 |
Use of antiepileptics during pregnancy: Clinician’s view
|
Fantaneanu, Tadeu |
|
2019 |
34 |
1S |
p. S7-S8 |
artikel |
257 |
Using electronic medical records to advance genomic medicine – novel approaches for finding actionable pharmacogenomics
|
Denny, Joshua |
|
2019 |
34 |
1S |
p. S6 |
artikel |
258 |
Using statistical analyses to demonstrate equivalency between automated and manual processes to deliver high quality in vitro adme data even faster
|
Amin, Jakal |
|
2019 |
34 |
1S |
p. S52 |
artikel |
259 |
Utility and limitations of dual cholate shunt assay in preclinical species
|
More, Vijay |
|
2019 |
34 |
1S |
p. S75 |
artikel |
260 |
Virtual cell models to predict binding and distribution of chemicals in in vitro toxicity assays
|
Fisher, Ciarán |
|
2019 |
34 |
1S |
p. S4 |
artikel |
261 |
Why is modelling of in vitro experimental data important?
|
Gardner, Iain |
|
2019 |
34 |
1S |
p. S2-S3 |
artikel |
262 |
Zebrafish as a screening model for testing the permeability of blood-brain barrier to small molecules
|
Kim, Seong Soon |
|
2019 |
34 |
1S |
p. S35 |
artikel |